ST3GAL1 regulates cancer cell migration through crosstalk between EGFR and neuropilin-1 signaling
Journal of Biological Chemistry · 2025
DOI: 10.1016/j.jbc.2025.108368 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2025. Verfasst von Tan-Chi Fan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Stem Cell and Translational Cancer Research, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan, Taiwan. Hauptthemen laut MEDLINE: Sialyltransferases, Neuropilin-1, ErbB Receptors, Cell Movement. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Chang Gung Medical Foundation, Academia Sinica, National Science and Technology Council.
Abstract (Originalsprache)
Metastasis is a major cause of cancer-related morbidity and mortality. The overexpression of the sialyltransferase ST3GAL1 in breast cancer correlates with metastasis. However, the molecular mechanisms underlying the effect of ST3GAL1 on cell movement are poorly understood. We identified neuropilin-1/NRP1 as a substrate for ST3GAL1. Gene expression analysis revealed that recurrence-free survival ( p = 0.0046) and distant metastasis-free survival ( p = 0.0003) were significantly shorter in the ST3GAL1 High NRP1 High cohort than in the both-low subgroup. We demonstrated that the ST3GAL1-mediated sialylation of NRP1 results in increased binding affinity toward EGFR at the molecular level. At the cellular level, ST3GAL1 silencing impaired cell migration and wound healing ability, which was linked to reduced activities of CAPN2 as a consequence of diminished EGF/EGFR signaling. These data establish a function for the ST3GAL1-mediated sialylation of NRP1, leading to increased EGF/EGFR downstream signaling and enhanced tumor cell motility. Furthermore, ST3GAL1 silencing augmented the sensitivity to cetuximab-mediated cell lysis. Our findings provide novel insight into the mechanisms underlying the function of ST3GAL1 in promoting tumor cell migration through the EGFR/NRP1 pathway. Our results suggest that ST3GAL1 may represent a valuable target for strategies aimed at inhibiting tumor migration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Stem Cell and Translational Cancer Research, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan, Taiwan.
- Institute of Stem Cell and Translational Cancer Research, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan, Taiwan; Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital, Linkou Branch, and Chang Gun…
- Division of Hematology-Oncology, Department of Pediatrics, Chang Gung Memorial Hospital, Linkou Branch, and Chang Gung University, College of Medicine, Taoyuan, Taiwan. Electronic address: samechen@cgmh.org.tw.
- Institute of Stem Cell and Translational Cancer Research, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan, Taiwan; Genomics Research Center, Academia Sinica, Taipei, Taiwan; Department of Pediatrics/Hematology Onco…
Förderung
- Chang Gung Medical Foundation
- Academia Sinica
- National Science and Technology Council
Zitieren
APA
Fan, T. C., Yeo, H. L., Hung, T. H., Chang, N. C., Tang, Y. H., Yu, J., Chen, S. H., & Yu, A. L. (2025). ST3GAL1 regulates cancer cell migration through crosstalk between EGFR and neuropilin-1 signaling. Journal of Biological Chemistry. https://doi.org/10.1016/j.jbc.2025.108368
Vancouver
Fan TC, Yeo HL, Hung TH, Chang NC, Tang YH, Yu J, et al. ST3GAL1 regulates cancer cell migration through crosstalk between EGFR and neuropilin-1 signaling. Journal of Biological Chemistry. 2025. doi:10.1016/j.jbc.2025.108368
BibTeX
@article{Fan2025,
author = {Fan, Tan-Chi and Yeo, Hui Ling and Hung, Tsai-Hsien and Chang, Nai-Chuan and Tang, Yun-Hsin and Yu, John and Chen, Shih-Hsiang and Yu, Alice L},
title = {ST3GAL1 regulates cancer cell migration through crosstalk between EGFR and neuropilin-1 signaling},
journal = {Journal of Biological Chemistry},
year = {2025},
doi = {10.1016/j.jbc.2025.108368}
}
EUVIMED